



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Yongsheng Zhao,
✉ scnczys@126.com
Hongpan Zhang,
✉ hongpanzhangscn@163.com

†These authors have contributed equally to
this work

RECEIVED 20 November 2024
ACCEPTED 21 November 2024
PUBLISHED 04 December 2024

CITATION
Zhao H, Luo K, Liu M, Cai Y, Liu S, Li S, Zhao Y and
Zhang H (2024) Corrigendum: Immune
regulation and prognostic prediction model
establishment and validation of PSMB6 in
lung adenocarcinoma.
Front. Genet. 15:1531321.
doi: 10.3389/fgene.2024.1531321

COPYRIGHT
© 2024 Zhao, Luo, Liu, Cai, Liu, Li, Zhao and
Zhang. This is an open-access article distributed
under the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other forums is
permitted, provided the original author(s) and
the copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

Haiyang Zhao^{1,2,3,4†}, Kexin Luo^{1,2,3,4†}, Meihan Liu^{1,2,4,5†},
Yuanze Cai², Siman Liu², Shijuan Li⁶, Yongsheng Zhao^{1,2,3*} and
Hongpan Zhang^{1,2,5,7*}

¹Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China, ²North Sichuan Medical College, Nanchong, China, ³Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China, ⁴North Sichuan Medical College, Innovation Centre for Science and Technology, Nanchong, China, ⁵Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China, ⁶Nanchong Central Hospital, Nanchong, Sichuan, China, ⁷Therapeutic Proteins Key Laboratory of Sichuan Province, Nanchong, China

KEYWORDS

lung adenocarcinoma, PSMB6, immunotherapy, immune infiltration, tumor immune microenvironment

A Corrigendum on Immune regulation and prognostic prediction model establishment and validation of PSMB6 in lung adenocarcinoma

by Zhao H, Luo K, Liu M, Cai Y, Liu S, Li S, Zhao Y and Zhang H (2024). *Front. Genet.* 15:1458047.
doi: 10.3389/fgene.2024.1458047

In the published article, there was an error regarding the **Affiliations** listed for Haiyang Zhao, Kexin Luo, Meihan Liu, Yongsheng Zhao and Hongpan Zhang. In addition to their existing **Affiliations**, they should also have Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China listed to their names.

The corrected **Affiliations** are listed below:

Haiyang Zhao^{1,2,3,4,†}, Kexin Luo^{1,2,3,4,†}, Meihan Liu^{1,2,4,5,†}, Yuanze Cai², Siman Liu², Shijuan Li⁶, Yongsheng Zhao^{1,2,3,*}, Hongpan Zhang^{1,2,5,7,*}

1. Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
2. North Sichuan Medical College, Nanchong, China
3. Department of Thoracic Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
4. North Sichuan Medical College, Innovation Centre for Science and Technology, Nanchong, China
5. Department of Oncology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China
6. Nanchong Central Hospital, Nanchong, Sichuan, China
7. Therapeutic Proteins Key Laboratory of Sichuan Province, Nanchong, China

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.